rheumatic muscloskeletal disease

Dr. Tobit Steinmetz is our guest this week, author of the manuscript recently published in “Arthritis and Rheumatology” titled: "Association of Circulating Antibody-Secreting Cell Maturity with Disease Features in Primary Sjogren's Syndrome." Dr. Steinmetz and his team endeavored to better understand the hyperactivity observed among B cells, which play a major role in Primary Sjogren’s Syndrome (SS). To do this, he and the team examined the quantity, maturity and inflammatory properties of Antibody Secreting Cells (ASCs) in the B cell effector branch, which became the focus of the study. Tune in to hear how this was done, what their observations and conclusions were plus, Dr. Steinmetz’s insights for those looking to enter a postdoctoral position! 

Patients with Rheumatoid Arthritis (RA) need rehabilitation to improve functional limitations and slow disability. But in what doses? Using the FORWARD databank, our next guest Dr. Kaleb Michaud, PhD, identified a cohort and gathered data on rehabilitation dose and their functional outcomes. His study’s objective (titled: “Examining Rehabilitation Dose in Adults With Rheumatoid Arthritis: Association With Baseline Factors and Change in Clinical Outcomes“) determine if there was a meaningful change in physical function, pain and fatigue over a six-month period when evaluating baseline factors and rehabilitation dose. This study, recently published in Arthritis Care & Research is the subject of our discussion today.